Iron at the Front Lines: A Practical Approach to IV Iron Management.

ANNA CE Satellite Symposium - Orlando Florida
May 23, 2002
Access to this symposium is free, but you must first be a registered FREE ZONE user of HDCN. If not already an HDCN FREE ZONE user, please register at this link and select a username and password.
Treatment and maintenance iron sucrose protocols
David Van Wyck, MD.
Iron agents, iron dosing, and monitoring iron status
Sheryl Salvato, RN.
Heart failure, kidney disease, and anemia
Donald Silverberg, MD.
Panel Discussion
Dr. Van Wyck, Ms. Salvato, Dr. Silverberg



After participating in this program, the learner should be able to:
  1. Understand how maintenance iron protocols affect anemia outcomes and total iron dose.
  2. To be able to identify clinical and laboratory stop points for iron therapy.
  3. Understand how available iron agents differ in preparation, pharmacokinetics, dosing, and evidence of safety.
  4. Understand how improving anemia in patients with CKD affects cardiac and functional status.
David Van Wyck, MD
Professor of Medicine and Surgery
The University of Arizona
College of Medicine
Tuscon, Arizona

Sheryl Salvato, RN
Clinic Manager
National Nephrology Associates
Austin, Texas

Donald Silverberg, MD
Senior Physician
Department of Nephrology
Tel Aviv Medical Center
Tel Aviv, Isreal

This satellite symposium is sponsored by an unrestricted educational grant from American Regent Laboratories, Inc. This activity has been planned and produced in accordance with CE guidelines and policies. From a CE symposium held on May 23, 2002 at the American Nephrology Nurses' Association (ANNA) Annual Meeting in Orlando, FL. This symposium was approved by ANNA. It was not part of the official ANNA Annual Meeting.
This activity has been awarded 1.5 contact hours by the American Nephrology Nurses Association (ANNA) which is accredited as a provider and approver of continuing education in nursing by the American Nurses Credentialing Center-Commission on Accreditation (ANCC-COA).
Posting Date: October 2002
CE Credit Eligible Through: October, 2003
CE Credit Hours/Completion Time: 1.5
Target Audiences: Nurses, nurse practitioners, and other healthcare professionals who treat and manage patients with CKD.
Method of participation: Listen to the talk, read the PubMed abstracts linked to data slides and talk references, take the post-test, read the linked abstracts in the post-test answer feedback material.

STATEMENT OF NEED :
Chronic kidney disease affects 30-40 million Americans, of whom several hundred thousand require renal replacement therapy. These selected lectures will allow nephrology nurses, pharmacists, and technicians to obtain up-to-date information about issues related to care of renal patients.

ACCREDITATION STATEMENT:
This continuing education activity is based on an approved Satellite Symposium which took place at the American Nephrology Nurses' Association (ANNA) 2002 Annual Meeting, and is approved by ANNA, East Holley Avenue, Box 56, Pitman, New Jersey 08071-0056, an accredited approver by the American Nurse Credentialing Center Commission on Accreditation (ANCC-COA). ANNA is an approved provider of CE to nursing by the California Board of Registered Nursing, BRN Provider No. 00910, the Alabama Board of Nursing, BRN Provider No. PO324, and the Kansas State Board of Nursing, Provider No. LT0148-0738. This course offering is applicable for RN and LPN licensure in Kansas. Licensees in the states of CA, AL, and KS must retain this certificate for four years after the CE activity is completed. Other mandatory CE states may have different record keeping requirements. Please be aware of your state's procedure.

The activity provider is HDCN, 15W560 89th St., Hinsdale, IL 60527.

FACULTY DISCLOSURE STATEMENTS :
The American Nephrology Nurses' Association, as well as HDCN have conflict of interest policies that require course faculty to disclose any real or apparent commercial financial affiliations related to the content of their presentations/materials. It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations; they are simply noted here to fully inform participants.

Dr. Van Wyck is a member of the Speakers Bureau for American Regent Laboratories, Inc and Amgen Inc.
S. Salvato is a member of the Speakers Bureau for American Regent Laboratories, Inc
Dr. Silverberg is a member of the Speakers Bureau for American Regent Laboratories Inc, Amgen, and Johnson and Johnson.
DISCLOSURE OF UNLABELED USE:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The American Nephrology Nurses' Association, and HDCN do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

This satellite symposium is sponsored by an unrestricted educational grant from American Regent Laboratories, Inc.
This activity has been planned and produced in accordance with CE guidelines and policies. From a CE symposium held on May 23, 2002 at the American Nephrology Nurses' Association (ANNA) Annual Meeting in Orlando, FL.
This symposium was approved by ANNA. It was not part of the official ANNA Annual Meeting.